We are live on ! Find out more
XENE icon

Xenon Pharmaceuticals
XENE

31 hedge funds and large institutions have $80.8M invested in Xenon Pharmaceuticals in 2016 Q4 according to their latest regulatory filings, with 6 funds opening new positions, 5 increasing their positions, 10 reducing their positions, and 5 closing their positions.

New
Increased
Maintained
Reduced
Closed

58.65% more ownership

Funds ownership: 0% → 58.65% (+59%)

20% more first-time investments, than exits

New positions opened: 6 | Existing positions closed: 5

3% more funds holding

Funds holding: 30 → 31 (+1)

0% more capital invested

Capital invested by funds: $80.6M → $80.8M (+$212K)

0% more funds holding in top 10

Funds holding in top 10: 3 → 3 (0)

50% less repeat investments, than reductions

Existing positions increased: 5 | Existing positions reduced: 10

Holders
31
Holders Change
+1
Holders Change %
+3.33%
% of All Funds
0.78%
Holding in Top 10
3
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.07%
New
6
Increased
5
Reduced
10
Closed
5
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

1
Capital World Investors
Capital World Investors
California
+$1.57M
2
Millennium Management
Millennium Management
New York
+$1.56M
3
SFM
Sphera Funds Management
Israel
+$803K
4
EIM
Essex Investment Management
Massachusetts
+$564K
5
California Public Employees Retirement System
California Public Employees Retirement System
California
+$442K

Top Sellers

1
HCMT
Highland Capital Management (Texas)
Texas
-$1.12M
2
Royal Bank of Canada
Royal Bank of Canada
Ontario, Canada
-$972K
3
BI
BVF Inc
California
-$523K
4
Point72 Asset Management
Point72 Asset Management
Connecticut
-$388K
5
PA
Perceptive Advisors
New York
-$181K
Name Holding Trade Value Shares
Change 		Change in
Stake
BI
1
BVF Inc
California
$23.4M -$523K -65,100 -2%
Capital World Investors
2
Capital World Investors
California
$9.43M +$1.57M +195,000 +19%
O
3
OrbiMed
New York
$7.7M – – –
PA
4
Perceptive Advisors
New York
$5.7M -$181K -22,528 -3%
TCM
5
Tekla Capital Management
Massachusetts
$5.39M – – –
DCM
6
DAFNA Capital Management
California
$3.96M – – –
OM
7
Opaleye Management
Massachusetts
$3.12M -$40.2K -5,000 -1%
IPC
8
Invesco Private Capital
New York
$3.08M -$94.8K -11,802 -3%
SFM
9
Sphera Funds Management
Israel
$2.53M +$803K +100,000 +44%
GTC
10
Ghost Tree Capital
New York
$2.5M – – –
IVM
11
InterWest Venture Management
California
$2.46M +$2.57M +320,061 New
Point72 Asset Management
12
Point72 Asset Management
Connecticut
$2.39M -$388K -48,352 -13%
Royal Bank of Canada
13
Royal Bank of Canada
Ontario, Canada
$1.9M -$972K -121,034 -33%
Millennium Management
14
Millennium Management
New York
$1.49M +$1.56M +193,674 New
NHAS
15
Novo Holdings A/S
Denmark
$982K – – –
Renaissance Technologies
16
Renaissance Technologies
New York
$879K +$145K +18,000 +19%
HCMT
17
Highland Capital Management (Texas)
Texas
$848K -$1.12M -139,787 -56%
EIM
18
Essex Investment Management
Massachusetts
$540K +$564K +70,172 New
State of New Jersey Common Pension Fund D
19
State of New Jersey Common Pension Fund D
New Jersey
$501K – – –
KPF
20
K2 Principal Fund
Ontario, Canada
$441K +$339K +42,228 +282%
California Public Employees Retirement System
21
California Public Employees Retirement System
California
$424K +$442K +55,000 New
PCM
22
Prelude Capital Management
New York
$269K +$280K +34,928 New
WMSA
23
Weiss Multi-Strategy Advisers
New York
$243K – – –
SC
24
Scotia Capital
Ontario, Canada
$160K -$16 -2 -0%
NSEDCP
25
NJ State Employees Deferred Compensation Plan
New Jersey
$154K – – –
1
2

XENE Hedge Fund Activity: Q4 2016 in Review

31 of the 4,000 institutional investors tracked by Wall St. Rank reported a position in Xenon Pharmaceuticals (XENE) for Q4 2016, worth a combined $80.8M — up 0.26% from $80.6M a quarter earlier.

Buyers outnumbered sellers: 6 funds opened new XENE positions and 5 closed out — a net gain of 1 holder — while 5 added to existing stakes and 10 trimmed.

The largest buyer was Capital World Investors, adding an estimated $1.57M. The largest seller was Highland Capital Management (Texas), cutting an estimated $1.12M.

  • 31 institutional investors held Xenon Pharmaceuticals (XENE) as of Q4 2016, up from 30 in Q3 2016.
  • Funds reported $80.8M of Xenon Pharmaceuticals stock for Q4 2016, up 0.26% quarter-over-quarter.
  • 6 funds opened new Xenon Pharmaceuticals positions in Q4 2016 and 5 closed out, a net change of +1 holder.
  • The largest Xenon Pharmaceuticals buyer in Q4 2016 was Capital World Investors, an estimated $1.57M added.
  • The largest Xenon Pharmaceuticals seller in Q4 2016 was Highland Capital Management (Texas), an estimated $1.12M sold.

Based on aggregated 13F filings for Q4 2016.